

Haematologica  
HAEMATOL/2017/171561  
Version 4

Consolidation treatment with lenalidomide following front-line or salvage chemoimmunotherapy in chronic lymphocytic leukemia

Paolo Strati, Michael J. Keating, Jan A. Burger, Susan M. O'Brien,  
William G. Wierda, Zeev Estrov, Gracy Zacharian, and Alessandra  
Ferrajoli

Disclosures: MJK was a consultant for Celgene Corporation; WGW was a consultant/advisory board member for Celgene Corporation; SMO was a consultant for Celgene Corporation; and AF and PS received research support from Celgene Corporation. The remaining authors declare no competing financial interests. The University of Texas MD Anderson Cancer Center is supported in part by the National Institutes of Health through Cancer Center Support Grant P30CA016672.

Contributions: AF designed, performed, and analyzed the trial, provided clinical care to patients, and wrote the paper; PS analyzed data, performed statistical analysis, and wrote the paper; MJK, WGW, SMO, JAB, ZE and GZ provided clinical care to patients and coauthored the paper.